Aims/hypothesis The CD40-CD154 interaction directs autoimmune inflammation. Therefore, a long-standing goal in the treatment of autoimmune disease has been to control the formation of that interaction and thereby prevent destructive inflammation. Antibodies blocking CD154 are successful in mouse models of autoimmune disease but, while promising when used in humans, unfortunate thrombotic events have occurred, forcing the termination of those studies. Methods To address the clinical problem of thrombotic events caused by anti-CD154 antibody treatment, we created a series of small peptides based on the CD154 domain that interacts with CD40 and tested the ability of these peptides to target CD40 and prevent type 1 diabetes in NOD mice. Results We identified a lead candidate, the 15-mer KGYY 15 peptide, which specifically targets CD40-positive cells in a size-and sequence-dependent manner. It is highly efficient in preventing hyperglycaemia in NOD mice that spontaneously develop type 1 diabetes. Importantly, KGYY 15 can also reverse new-onset hyperglycaemia. KGYY 15 is well tolerated and functions to control the cytokine profile of culprit Th40 effector T cells. The KGYY 15 peptide is 87% homologous to the human sequence, suggesting that it is an important candidate for translational studies. Conclusions/interpretation Peptide KGYY 15 constitutes a viable therapeutic option to antibody therapy in targeting the CD40-CD154 interaction in type 1 diabetes. Given the involvement of CD40 in autoimmunity in general, it will also be important to evaluate KGYY 15 in the treatment of other autoimmune diseases. This alternative therapeutic approach opens new avenues of exploration in targeting receptor-ligand interactions.
Introduction
Although the aetiology of autoimmunity is not clear, CD40-CD154 interactions are critical in the development and perpetuation of autoimmune disease [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] . CD40 is expressed on antigen-presenting cells (APCs) [12] , but it is expressed more ubiquitously, including on T cells [13] [14] [15] . We identified a CD4 + T cell subset that expresses CD40, known as Th40 cells, which is necessary and sufficient for transferring diabetes in a mouse model of type 1 diabetes [9, [14] [15] [16] [17] . CD40 drives the disease process: CD40 −/− and CD154 −/− mice do not develop autoimmune disease [18, 19] .
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CD40 is a member of the TNF receptor superfamily [20] . The natural ligand for CD40, CD154 [21] , occurs in both membrane-bound and soluble forms. CD154 interacts not only with CD40 but also with α5β1 and αIIbβ3 integrins, which may be critical to its signalling function [22] . CD154 may serve as a molecular bridge between these receptors: simultaneous CD154 binding to CD40 and α5β1 induced stronger signalling than binding to each receptor separately [22] . The dynamic CD40-CD154 dyad controls many inflammatory events in B cells [23] , macrophages [24] , monocytes [25] and dendritic cells [26] , as well as in T cells [4, 7, 27] .
The involvement of CD40 signalling in driving inflammatory events and autoimmunity has led to the CD40-CD154 dyad becoming a primary therapeutic target. By blocking the signal, control of the destructive inflammation becomes possible. However, considering that CD154 interacts with other receptors [22] , it is important to tailor the inhibition to avoid undesired consequences. While CD40 antibodies are agonistic in nature, CD154-blocking antibodies are available and can prevent or ameliorate autoimmune disease in several disease models [2, 6, 28] , including type 1 diabetes [1, 9] . Anti-CD154 treatment also demonstrated promise in human systemic lupus erythematosus (SLE) [29, 30] . However, unfortunate life-threatening thrombotic events arose, leading to termination of the studies [29, 31] . As a consequence of that result and other antibody-related side effects, it is desirable to find alternative means of inhibiting the CD40-CD154 interaction. Random peptides that inhibit CD40-CD154 interaction have been tested. However, as a consequence of their random nature, they may inhibit other interactions when employed in vivo [32, 33] , and some require to be used at high concentrations [32] . In a more targeted approach, a peptide was designed based on a CD154 domain [34] surrounding one of the amino acids involved in the CD40-CD154 interaction [35, 36] . That peptide demonstrated very low efficacy in blocking experimental autoimmune encephalomyelitis (EAE) [34] . Some small molecule organic compounds inhibited CD40-CD154 interaction but lost their activity in protein-rich medium [37] , suggesting further nonspecific effects. These compounds are structurally similar to suramin [38] , which has toxic side effects [39] .
Peptides are commonly used as human therapeutics and have a good safety record [40] [41] [42] . Therefore, based on the potential for peptides to interrupt receptor-ligand interactions we adopted a targeted approach to inhibit the CD40-CD154 interaction. From the CD154 domain critical for interaction with CD40, we designed different-sized peptides spanning several interacting amino acids [35, 36] . This region is 87% identical between humans and mice, suggesting that it forms a functionally important part of CD154. Importantly, this region is not critical for CD154 interaction with other receptors [22] . We tested these peptides in the NOD mouse model of type 1 diabetes by assessing their specificity for CD40 and their ability to prevent and reverse diabetes onset. 15 , VLQWAEKGYYTMSNN) were purchased from New England Peptide (Gardner, MA, USA) and were >98% pure. Anti-CD40 (1C10) and anti-CD4 (GK1.5) antibodies were produced in house. IFN-γ (XMG1.2), TNF-α (MP6-XT22), IL-17A (eBi017B7), IL-6 (MP5-20F3) and IL-2 (JES6-SH4) were obtained from eBioscience (San Diego, CA, USA). Anti-CD40 and anti-hsp70 antibodies, and secondary antibodies used for western blotting (sc-975, sc-33575, sc-2004, sc-2005) were obtained from Santa Cruz Biotechnology (Dallas, TX, USA).
Methods

Mice
Prevention and reversal of diabetes For prevention studies, 25 μg peptide (a dose of 1 mg/kg) in 100 μl PBS was administered by weekly i.v. injection for 20 weeks, beginning at 5 weeks of age. Blood glucose was monitored weekly until 36 weeks of age. Animals with three consecutive blood glucose measurements >13.9 mmol/l were considered diabetic.
For diabetes reversal studies, starting at 10-12 weeks of age, blood glucose levels were monitored daily until diabetes onset (blood glucose >13.9 mmol/l), and then 100 μg peptide (a dose of 4 mg/kg) was administered by daily i.v. injection for 6 days or longer.
Cell purification and flow cytometry Spleens were homogenised in red blood cell lysing buffer (Sigma-Aldrich, St Louis, MO, USA), washed, and then the cells were either stained immediately or sorted into Th40 and APC populations, as previously described [8] , and then stained. Lymph node lymphocytes were isolated using Lympholyte-M (Cedarlane Labs, Burlington, NC, USA). Intracellular staining was performed on cells that were fixed immediately after isolation, without ex vivo stimulation, using permeabilisation buffer (eBioscience). Flow cytometry was performed using a MACSQuant Analyzer (Miltenyi Biotec, Auburn, CA, USA) and analysis was performed using FlowJo software (Ashland, OR, USA).
Peptide pull down and western blotting Splenic CD4 hi , CD4 lo (Th40), CD8 and MHCII (APCs) cells were sorted as previously described [8, 43] . Cells were lysed in 20 mmol/l TrisHCl pH 7.5, 2 mmol/l EDTA, 137 mmol/l NaCl, 0.1% Triton X-100, 1 μg/ml each leupeptin and aprotinin, 0.2 mmol/l phenylmethanesulfonyl fluoride, and 0.4 mmol/l sodium orthovanadate. KGYY 15 or scrambled peptide conjugated to Tosyl-activated magnetic beads (Invitrogen, Grand Island, NY, USA) was immediately added to cell lysates and incubated for 20-30 min. Beads were washed three times with lysis buffer before elution of bound material. Western blots were performed as previously described [8] .
Serum antibody and T cell antigen recall tests Serum and splenic cells were collected from mice that had been injected weekly for 7 weeks with 1 mg/kg KGYY 15 Histology Fixed and sectioned pancreases were stained with haematoxylin and eosin (H&E) or aldehyde fuchsin. Scoring for insulitis and insulin granules was conducted as indicated in the figure legends. More than 100 islets were scored in each group.
Data analysis Data analysis was performed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA) using tests indicated in the text and figure legends.
Results
Peptides spanning several amino acids critical to CD40-CD154 interaction Given the plethora of clinical problems associated with antibodies for immune intervention, it is essential to employ alternative means to inhibit inflammatory interactions. We designed peptides based on a domain of the CD154 protein sequence known to be critical for binding to CD40 (Fig. 1a) . The peptides span three of the five amino acids in human CD154 required for interaction with CD40: K143, Y145 and Y146 ( Fig.1a ; amino acids in bold; K142, Y144 and Y145 in the mouse sequence) [35, 36] . A 15 amino acid stretch of this region is 87% identical between mouse and human sequences ( Fig. 1a ; boxed, analysed by BLASTp at the National Center for Biotechnology Information; http://blast.ncbi.nlm.nih. gov/), indicating that it is a functionally important part of the protein. In contrast, a previously studied peptide that demonstrated very low efficacy in inhibiting EAE ( Fig. 1a ; in blue) [34] has only 64% homology to the human CD154 sequence.
A 15 amino acid sequence is the optimal size for diabetes prevention In order to determine whether peptides from the region described above are efficacious in preventing diabetes, 5-week-old NOD mice were treated with 8-mer, 10-mer, 13-mer, 15-mer and 24-mer peptides spanning the KxYY motif ( Fig. 1a; shown in bold). The 15-mer peptide was highly efficacious in preventing diabetes, with only 10% of treated mice becoming diabetic, while the 13-mer peptide demonstrated some ability in preventing diabetes, with only 30% of treated mice becoming diabetic (Fig. 1b) peptides significantly (p<0.0001) delayed diabetes onset in mice that did become diabetic, with the 15-mer peptide outperforming the 13-mer peptide (p<0.0001). The smaller peptides were unable to prevent diabetes, although they could delay the onset ( Fig. 1b; p<0 .0001). The 24-mer peptide showed no efficacy at all, resulting in a diabetes incidence rate identical to that of the untreated group (Fig. 1b) . The fluctuation in diabetes incidence at weeks 30 and 31 in the 15-mer peptide-treated group was the result of a single mouse that became diabetic despite the treatment but reverted to euglycaemia with continued treatment.
Diabetes prevention by the KGYY 15 15-mer peptide is sequence specific As shown in Fig. 1b , the 15-mer peptide (referred to as KGYY 15 ) was the most efficacious in diabetes prevention. A scrambled version of KGYY 15 completely lacked the ability to prevent diabetes ( Fig. 2a; sequences noted above graph). Additionally, a peptide spanning the RGD region of CD154, which is known to interact with αIIbβ3
[22], did not prevent diabetes ( Fig. 2a; sequence noted above graph).
Additional amino acids are critical for the interventional efficacy of KGYY 15 Given that the size of the peptide, as well as its amino acid sequence, was shown to be critical for its function, we performed a structure-activity relationship (SAR) study by creating a peptide series in which single amino acids were replaced with glycine. This substitution strategy revealed that L137, Y144, T146, M147 and N150 are critical for the in vivo intervention function ( Fig. 2b ; no other single substitutions altered efficacy). Curiously, substitution of T146 for glycine increased diabetes incidence to 100% (Fig. 2b) . When Y145, shown to be critical for CD154 interaction with CD40 [35, 36] , was exchanged for a glycine residue, there was no reduction in the interventional efficacy of the peptide. Importantly, all of the amino acids shown to be critical for peptide efficacy are conserved between the mouse and human sequences ( Fig. 2b ; compare with Fig. 1a ).
KGYY 15 ameliorates insulitis Although the specific mechanism is unknown, blocking CD154 prevents diabetes [1] and also insulitis [9] , which is defined as the infiltration of T cells and other immune cells into beta islets. We determined the extent of insulitis by comparing KGYY 15 -treated pancreases to diabetic NOD mouse pancreases (Fig. 3a, b) . KGYY 15 treatment did not prevent immune cell infiltration into the pancreas itself but, importantly, prevented entry into beta islets, as demonstrated by the peri-insulitis pattern in H&E stained sections (Fig. 3a) . Scoring the infiltration levels of the islets revealed that, while 39% of the diabetic pancreatic islets demonstrated a score of 3 or 4, only 13% of the KGYY 15 -treated islets showed a score at that level, and the majority (72%) scored 0 or 1 (Fig. 3c) .
KGYY 15 reverses overt hyperglycaemia While the ability of KGYY 15 to prevent type 1 diabetes onset in mice is evident, it is not easy to predict the development of type 1 diabetes in humans and it is not feasible to treat everybody with the goal of preventing disease in a subset of the population. Therefore, it is highly desirable to be able to effectively treat the disease once it is diagnosed. With this goal in mind, we allowed NOD mice to progress to diabetes (blood glucose >13.9 mmol/l), and then new-onset diabetic mice received a 4 mg/kg daily dose of KGYY 15 . Using this strategy, 56% of diabetic animals returned to euglycaemia after 1-2 days (Fig. 4a, b) . Additionally, KGYY 15 treatment initiated after hyperglycaemia onset significantly improved insulitis (Fig. 4c) , as well as insulin granule (Fig. 4d) (Fig. 5a ). APCs are known to express CD40. Therefore, as a comparison, we stained splenic MHCII + cells that had been depleted of CD4 and CD8, and found that 64% of APCs showed double positive staining for KGYY 15 and CD40 (Fig. 5b) (Fig. 5c ). CD40 was also readily pulled down from Th40 cells, but two smaller and one larger band were present (Fig. 5c ), which may represent differentially glycosylated CD40 protein, as we have demonstrated before for this cell type [44, 45] . A scrambled version of KGYY 15 did not pull down any CD40 protein bands, thus demonstrating the specificity of the interaction between KGYY 15 and the CD40 protein (Fig. 5c ). Hsp70, which is known to non-specifically bind peptides, was assayed as a control. The scrambled peptide was as efficient as KGYY 15 in pulling down Hsp70 protein, demonstrating that the scrambled peptide is functional and further indicating the specificity of KGYY 15 (Fig. 5c ).
KGYY 15 does not appear to elicit peptide-specific antibody production or T cell antigen recall An important aspect to consider in the peptide treatment of disease is whether the peptide itself elicits an antigen response. We could not detect serum antibodies against the peptide or recombinant soluble CD154 in mice that had been treated with KGYY 15 for 7 weeks [electronic supplementary material (ESM) Fig. 1a] . Similarly, when T cells from treated mice were exposed to autologous APCs loaded with peptide, we could not detect proliferation (ESM Fig. 1b) . In addition, mice did not demonstrate any discomfort during administration of the treatment. Therefore, we conclude that the peptide does not elicit a discernible immune response.
KGYY 15 alters cytokine production by Th40 cells In addressing the mechanism of KGYY 15 action, we examined its impact on cytokine production by Th40 cells. KGYY 15 treatment significantly reduced the production of several inflammatory cytokines by Th40 cells, as measured in cells from peripheral and pancreatic lymph nodes immediately after their removal (Fig. 6 ). IFN-γ production, which is strongly associated with diabetes progression, was significantly reduced, along with TNF-α and IL-6, in peripheral lymph nodes, while IL-2 was not affected. TNF-α, IL-6 and IL-2 levels were significantly reduced in pancreatic lymph node Th40 cells. In splenic Th40 cells, there was a reduction in several cytokines, although this was not statistically significant.
Discussion
A long-term goal in the treatment of autoimmune disease has been to control the CD40-CD154 interaction. Initial studies utilising an antibody against CD154 were highly successful in animal models of autoimmune diseases [1, 6, 9, 28] . However, when translational studies were performed in SLE patients, life-threatening thrombotic events occurred and the studies were halted. Ironically, though, the CD40-CD154 block was successful [29, 31] . This fact and other inherent problems in the therapeutic use of antibodies, including the induction of antibody production directed against the treatment antibody and Fc-receptor binding, have intensified the hunt for an alternative means of inhibiting the CD40-CD154 interaction.
Here, we demonstrate that through analysing a series of small peptides targeting CD40, a lead candidate for drug development has emerged. A 15 amino acid sequence, KGYY 15 , based on the CD154 domain critical for interacting with CD40, specifically binds CD40 + T cells and APCs from autoimmune NOD mice. These results suggest that KGYY 15 can affect several compartments of the adaptive immune system to stem inflammatory responses.
KGYY 15 has the advantages of being both small and derived from an endogenous protein that is expressed under normal conditions. Therefore, the likelihood of host tolerance to KGYY 15 is high. Indeed, we could not detect the presence of autoantibodies to KGYY 15 or CD154, nor could we elicit T cell antigen recall. The KGYY 15 peptide was well tolerated by NOD mice injected weekly for 20 weeks and, importantly, prevented diabetes onset. In addition, in NOD mice that were allowed to progress to overt diabetes, albeit new onset, before any treatment was initiated, hyperglycaemia was reversed by administration of KGYY 15 . This indicates that KGYY 15 
. Western blots are shown for CD40 (top panels) and hsp70 (bottom panels). The experiment was performed three separate times actually destroyed by inflammation or is their insulin production simply 'turned off' or downregulated? From our data it appears, at least in the early stages of overt diabetes, that beta cells can reinitiate insulin production when pathological conditions, i.e. the inflammatory environment, are controlled. This suggests that the inflammatory milieu dictates whether beta islet cells can induce insulin expression in response to increased glucose levels. A pattern of peri-insulitis was observed instead of complete beta islet infiltration and cytokine production was altered, demonstrating that KGYY 15 , while not completely able to prevent trafficking to the pancreas, can block entry to the beta islets themselves, thus preserving beta cell integrity.
Peptide size and amino acid sequence are crucial to the interventional activity of KGYY 15 . SAR data revealed critical amino acid positions in the peptide that had not been detected in earlier CD40-CD154 interaction studies [35, 36] . Clearly, our in vivo functional study differs from previous in vitro mutagenesis studies, and it is also important to note that a peptide (KGYY 15 ) may interact differently than a larger protein (i.e. CD154). Surprisingly, a methionine residue (M147; position 12 in the 15-mer) is required for in vivo function of the peptide. Methionine is oxidation susceptible and is often replaced in therapeutic peptides, yet both this data and stability determination models show that the current 15-amino-acid configuration is extremely stable (100 h, as predicted by ExPASy ProtParam).
The thrombotic events that occurred in anti-CD154 antibody clinical trials were caused by platelet activation by the antibody. The KGYY 15 peptide does not have the inherent problems that antibodies carry as therapeutics. It is also not directed against CD154, but rather binds to CD40, which makes a thrombotic problem less likely.
Our data have important implications for new treatment strategies and drug development in autoimmune inflammation. As stated previously, controlling the CD40-CD154 dyad is a critical element in controlling autoimmune inflammation. Previously, the problem has been how to do this safely. KGYY 15 treatment represents a major step in that direction, and the fact that this protein sequence is highly conserved (87%) suggests that it would be an excellent candidate for translational studies. Important future studies will include determining the optimal KGYY 15 dose and treatment interval, and whether starting treatment later in the process that eventually leads to overt hyperglycaemia is efficacious. This research also opens other avenues for investigation: the development of peptides to directly target known receptors, for example cytokine and chemokine receptors.
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